Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors.
In: Contify Life Science News, 2024-02-29
Zeitungsartikel
Zugriff:
Titel: |
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors.
|
---|---|
Zeitschrift: | Contify Life Science News, 2024-02-29 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|